NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
George D. Demetri(Dana-Farber Cancer Institute), John Zalcberg(Monash Health), Haesun Choi(The University of Texas Health Science Center at Houston), Jeffrey D. Wayne(Northwestern University), Maria Dêbiec‐Rychter(Center for Human Genetics), Douglas S. Tyler(University of North Carolina at Chapel Hill), David S. Ettinger(Johns Hopkins University), Ronald P. DeMatteo(University of Pennsylvania), Christopher L. Corless(Oregon Health & Science University), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), George A. Fisher(Stanford University), Charles D. Blanke(SWOG Cancer Research Network), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Peter Hohenberger(University of Mannheim), Alberto S. Pappo(St. Jude Children's Research Hospital), Peter Reichardt(Helios Hospital Berlin-Buch), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Ian Judson(Erasmus Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Michael A. Morse(Duke Medical Center), Annick D. Van den Abbeele(Unknown), Margaret von Mehren(Temple University Health System), Heikki Joensuu(Orion Corporation (Finland)), Axel Le Cesne(Institut Gustave Roussy), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), Miranda Hughes(National Comprehensive Cancer Network)
Cited by 636
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k